Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

FDA Approves Blenrep for Patients with Relapsed or Refractory Multiple Myeloma

ASCO 2020 Highlights

On August 5, 2020, the FDA accelerated the approval of Blenrep (belantamab mafodotin-blmf; from GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

Blenrep is the first BCMA-directed therapy approved by the FDA for patients with multiple myeloma.

The FDA approved Blenrep for intravenous infusion based on results from the DREAMM-2 clinical trial that compared 2 different dosages of this drug. Patients received either 2.5 mg/kg of Blenrep, intravenously, or 3.4 mg/kg, intravenously, once every 3 weeks until their disease progressed, or until they had unacceptable side effects.

The determination of the benefit of Blenrep was based on the overall response rate to the treatment and the length of response, as determined by an independent review committee.

The overall response rate to Blenrep therapy was 31% among those patients who received the dose of 2.5 mg/kg, meaning that almost one-third of the patients had a positive response to therapy. Of those who had a response to therapy, the majority (73%) had a response that lasted 6 months or more. Because these results were observed in patients who received the dose of 2.5 mg/kg, this is now the recommended dose of Blenrep.

The prescribing information of Blenrep includes a boxed warning alerting doctors that Blenrep can cause changes in vision resulting from damage to the cornea, and these can lead to severe vision loss and corneal ulcer, as well as symptoms of blurred vision and dry eyes. Therefore, before each dose, patients should have their eyes checked, as well as when any symptoms are developed while using Blenrep.

Because of the risk of vision-related side effects, this medication can only be prescribed through a program called Risk Evaluation and Mitigation Strategy (or REMS), to ensure that proper precautions are taken when prescribing Blenrep.

In addition to these visual side effects, other side effects reported with Blenrep were nausea, fever, fatigue, and infusion-related reactions.

Recommended For You